替罗非班联合瑞替普酶在ST段抬高性急性心肌梗死中的疗效观察  

Effect of tirofiban combined with reteplase in patients with ST segment elevation acute myocardial infarction

作　　者：戴树人[1] 李芝峰[1] 廖荣宏[1] 李晓丽[1] 高崇瀚[1] 杨爽[1] 陈紫君[1] 

机构地区：[1]重庆医科大学附属永川医院心内科,402160

出　　处：《重庆医学》2014年第21期2720-2721,2724,共3页Chongqing medicine

摘　　要：目的观察常规剂量替罗非班联合半剂量瑞替普酶在ST段抬高性急性心肌梗死中的溶栓效果与安全性。方法选取2011年1月至2013年3月于该院进行治疗的60例ST段抬高性急性心肌梗死患者,分为瑞替普酶组(对照组,n=32)和替罗非班联合瑞替普酶组(观察组,n=28),比较两组患者不同时间的梗死相关血管再通率、并发症发生率。结果观察组不同时间梗死相关血管再通率均高于对照组(P<0.05),两组并发症发生率差异无统计学意义(P>0.05)。结论常规剂量替罗非班联合半剂量瑞替普酶在ST段抬高性急性心肌梗死中的溶栓效果较佳,且不增加并发症发生率。Objective To study the thrombolysis effect and safety of tirofiban combined with half dose reteplase in patients with ST segment elevation acute myocardial infarction .Methods 60 patients with ST segment elevation acute myocardial infarction in our hospital from January 2011 to March 2013 were selected as research object ,and they were divided into reteplase group （control group ,n=32） and tirofiban combined with reteplase group （observation group ,n=28） ,then the recanalization rate of infarct-relat-ed artery at different time and incidence of complications were compared .Results The recanalization rate of infarct-related artery of observation group at different time were all higher than those of control group （P〈0 .05） ,while incidence of complications of two groups had no significant difference（P〉0 .05） .Conclusion The thrombolysis effect of tirofiban combined with half dose reteplase in patients with ST segment elevation acute myocardial infarction is better ,and it does not increase the incidence of complications .

关 键 词：替罗非班 瑞替普酶 ST段抬高性急性心肌梗死 溶栓 并发症 

分 类 号：R542.22[医药卫生—心血管疾病]